Gradual dose reduction and medication tapering: A clinical perspective

Consultant Pharmacist

Volumn 22, Issue 8, 2007, Pages 628-644

  Beier, Manju T ^a,b   Martin, Caren McHenry ^c  

^a Geriatric Consultant Resources LLC   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c NONE

Author keywords

Alzheimer's disease; Antidepressant; Antipsychotic; Consultant pharmacist; Dementia; Depression; Elderly; Gradual dose reduction; Hypnotic; Nursing facility; Psychotropic; Sedative; State operations manual; Tapering

Indexed keywords

AMFEBUTAMONE; BENZODIAZEPINE DERIVATIVE; CHOLINESTERASE INHIBITOR; CITALOPRAM; DIPHENHYDRAMINE; DONEPEZIL; DULOXETINE; ESCITALOPRAM; ESZOPICLONE; FLUOXETINE; FLUVOXAMINE; HYDROXYZINE; MEMANTINE; MIRTAZAPINE; OLANZAPINE; PAROXETINE; PLACEBO; PSYCHOTROPIC AGENT; QUETIAPINE; RAMELTEON; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; ZALEPLON;

AGGRESSION; AGITATION; ALZHEIMER DISEASE; DEMENTIA; DEPRESSION; DRUG DOSE REDUCTION; DRUG EFFICACY; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GERIATRICS; GOVERNMENT REGULATION; GRADUAL DOSE REDUCTION; HALLUCINATION; HEALTH STATUS; HUMAN; INSOMNIA; LONG TERM CARE; MAJOR DEPRESSION; MEDICATION MANAGEMENT; MEDICATION TAPERING; MENTAL DISEASE; NURSING CARE; NURSING HOME; PATIENT COMPLIANCE; PHARMACIST; PRACTICE GUIDELINE; RECURRENT DISEASE; RELAPSE; REMISSION; REVIEW; RISK BENEFIT ANALYSIS; SENSORY DYSFUNCTION; SLEEP DISORDER; SYMPTOM; TOTAL QUALITY MANAGEMENT; TREATMENT DURATION; WITHDRAWAL SYNDROME;

EID: 34548045556     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2007.628     Document Type: Review

References (23)

1. Centers for Medicare & Medicaid Services. State Operations Manual. Appendix P, 2006.
2. Centers for Medicare & Medicaid Services. State Operations manual. F329, 2006.
3. Lyketsos CG, Lopez O, Jones B et al. Presence of neuropsychiatric symptoms in dementia and mild cognitive impairment. JAMA 2002;288:1475-83.
4. Devanand DP, Jacobs DM, Tang MX et al. The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry 1997;54:257-63.
5. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia. JAMA 2005;294:1934-43.
6. Briesacher, BA, Limcangco, R, Simoni-Wastila L et al. The quality of antipsychotic drug prescribing in nursing homes. Arch Intern Med 2005;165:1280-5.
7. Schneider LS, Tariot PN, Dagerman KS et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006;355:1525-38.
8. Centers for Medicare & Medicaid Services. State Operations Manual. F329, 2006.
9. Centers for Medicare & Medicaid Services. State Operations manual. F329, Table 1, 2006.
10. NIH State-of-the-Science Conference Statement on Manifestations and Management of Chronic Insomnia in Adults. NIH Consens Sci Statements 2005;22:1-30.
11. Lebowitz BD, Pearson JL, Schneider LS et al. Diagnosis and treatment of depression in late life: consensus statement update. JAMA 1997;278:1186-90.
12. Baldwin RC, Anderson D, Black S et al. Guideline for the management of late-life depression in primary care. Int J Geriatr Psychiatry 2003;18:829-38.
13. Questions and answers about the NIMH Sequenced Treatment Alternatives to Relieve Depression (STAR-D) Study. Available at http://www.nimh.nih.gov/ healthinformation/stard.cfm.
14. Tariot PN, Cummings JL, Katz IR et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc. 2001;49:1590-9.
15. Tariot PN, Solomon PR, Morris JC et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000;54:2269-76.
16. Trinh NH, Hoblyn J, Mohanty S et al. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer's disease: a meta-analysis. JAMA 2003;289:210-6.
17. Beier MT. Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention. Pharmacotherapy. 2007;27:399-411.
18. Cummings JL, McRae T, Zhang R. Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. Am J Geriatr Psychiatry 2006;14:605-12.
19. Centers for Medicare & Medicaid Services. State Operations manual. F329, 2006.
20. Centers for Medicare & Medicaid Services. State operations manual. F329, 2006.
21. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005:352;1112-20.
22. Gartlehner G, Hansen RA, Thieda P et al. Comparative effectiveness of second-generation antidepressants in the pharmacologic treatment of adult depression. Comparative Effectiveness Review No. 7. Agency for Healthcare Research and Quality. 2007. Available at www.effectivehealthcare.ahrq.gov/ reports/final.cfm.
23. Beier MT. The serotonin syndrome revisited. J Am Med Dir Assoc 2005;6:281.